PARKINSONS DISEASE THERAPEUTICS MARKET ANALYSIS

Parkinsons Disease Therapeutics Market, By Drug Class (Levodopa, Dopamine agonists, MAO-B inhibitors, Anticholinergics, Others (Catechol-O-methyl transferase [COMT] inhibitors and amantadine, among Others)), By Route of Administration (Oral, Injectable, Nasal, Transdermal, Others (Rectal, Sublingual, among Others)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

Published In : Oct 2023
Code : CMI494
Pages :312
Formats :
Excel and PDF
Industry : Pharmaceutical

Parkinsons Disease Therapeutics MarketSize and Trends

The global Parkinsons disease therapeutics market is estimated to be valued at US$ 5.11 Billion in 2023 and is expected to exhibit a CAGR of 7.0% during the forecast period (2023-2030).

Global Parkinsons Disease Therapeutics Market– Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID-19) pandemic has had a devastating influence on the lives of many families across the world, as well as healthcare institutions and the global economy. During the COVID-19 epidemic, patients had trouble getting their regular Parkinson's disease therapeutics. For instance, in August 2020, according to the International Parkinson and Movement Disorder Society, the impact of COVID-19 on the quality of healthcare reported by Parkinson's disease patients found that COVID-19 reduced the quality of healthcare as well as worsened the symptoms and interrupted the access to medication for Parkinson’s disease patients. Access to PD medication was negatively impacted by closing the routine clinical space, faltering delivery systems, and the inability to access dispensaries or pay for medication.